<DOC>
	<DOCNO>NCT01815723</DOCNO>
	<brief_summary>This multicenter , randomise , double-dummy , Fumaderm® placebo-controlled , parallel-group study compare efficacy safety 500 mg FP187 ( 250 mg twice daily ) compare 720 mg Fumaderm® ( 240 mg three time daily ) 20 week treatment . After initial wash-out non-drug treatment phase 1 6 week , patient receive allocate Study treatment up-titrated relevant dose level ( i.e. , 500 mg daily FP187 , 720 mg daily Fumaderm® , placebo ) . The up-titration full dose last 4 week FP187 9 week Fumaderm® . After 20 week treatment , patient ask enter separate open label treatment protocol expect continue 5 year .</brief_summary>
	<brief_title>Efficacy Study Dimethyl Fumarate Treat Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; clinical diagnosis stable moderate severe plaque psoriasis least 6 month ; clinical diagnosis plaque psoriasis affect body surface area le 10 % least 10 PASI scale sPGA score least moderate ; Besides psoriasis , patient good general health Patients DLQI score least 10 Pustular form psoriasis , erythrodermic guttate psoriasis ; Known immunosuppressive disease ; Presence another serious progressive disease include skin malignancy ; Active skin disease ; Use topical medical treatment UVB treatment 2 week precede randomization ; Use systemic antipsoriatic treatment precede randomization : methotrexate , cyclosporine , steroid PUVA ( psoralen + UVA treatment ) treatment within 4 week ; biological treatment within 12 week ; Stelara within 20 week ; acitretin within 6 month ; Treatment Fumaderm® Dimethyl Fumarate containing product within 12 week prior randomization ; Treatment drug influence course psoriasis ( e.g. , antimalarial drug , lithium ) within 4 week prior randomization ; Treatment retinoids , immunosuppressive treatment , cytostatics drug know harmful effect kidney within 3 month prior randomization ; Ongoing stomach intestinal problem ; Aspartate transaminase ( AST ) , Alanine transaminase ( ALT ) &gt; 2 x upper normal limit ( ULN ) , Gammaglutamyltransferase ( γGT ) &gt; 2.5 x ULN ; Creatinine Clearance &lt; 60 ml/min ; Leucopenia , eosinophilia lymphopenia ; Protein urine test ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Dimethyl fumarate</keyword>
	<keyword>Fumaderm®</keyword>
</DOC>